In the B16-huCD19 tumor model, significantly more IL-18 and IL-23, as well as a trend towards more IL-22 and IFNγ was detected in serum of mice receiving combination treatment when compared to mice receiving CART alone (Fig. 5b, c and Supplementary Fig. 10b). This evidence concerns the gene IL18 and neoplasm.